Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in obese patients with heart failure with preserved ejection fraction
NCT06391710Phase 2Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2024
- Primary completion
- Jan 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing HRS9531 with Placebo (2 arms). Primary endpoints: Kansas City Cardiomyopathy Questionnaire Clinical Summary at 36 weeks and Body Weight at 36 weeks. Started May 2024; status: active, not recruiting.
02
Drugs
HRS9531
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06391710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391710.